Remove 2020 Remove Leads Remove Side effects
article thumbnail

Influencer marketing in pharma

World of DTC Marketing

bil­lion in 2020, ac­cord­ing to In­flu­encer Mar­ket­ing Hub , which es­ti­mat­ed the mar­ket would grow to $13.8 At the same time, over­all dig­i­tal ad spend in the phar­ma space sky­rock­et­ed 242% year over year from Jan­u­ary to Feb­ru­ary in 2020 and 2021, Me­di­aRadar re­port­ed. bil­lion in 2021.

Marketing 192
article thumbnail

First nasal monoclonal antibody COVID-19 treatment shows potential

European Pharmaceutical Review

We discovered a way to shut down inflammation… in a patient with multiple sclerosis as well as in healthy patients,” stated lead author Thais Moreira, PhD, an assistant scientist at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital and an instructor in Neurology at Harvard Medical School.

article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

This is especially beneficial as a way of decreasing potential side effects. In the years 2015 and 2020, clinical-stage cancer programmes increased by a considerable 77 percent (1,642 to 2,911), resulting in a quarter of drugs currently in development worldwide being highly potent.

article thumbnail

Santhera seeks speedy FDA review of Duchenne drug vamorolone

pharmaphorum

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.

FDA 84
article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. The present unmet needs within chronic pain are not met with opioid therapies.

Medicine 102
article thumbnail

How Real-World Data Can Contribute to Improved Mental Health Treatment

PM360

And Mental Health America (MHA) found that between 2019 and 2020, 54.7% They’re wonderful medications, blockbuster sales, but real side effects. I think the best way is to come up with alternatives that don’t have these side effects, because then the problem is solved. above pre-pandemic levels by Q2 2022.